Suppr超能文献

血清蛋白质组谱在肝结直肠转移中的临床和预后价值:一项前瞻性初步研究。

Clinical and prognostic usefulness of serum proteomic profile in hepatic colorectal metastases: a pilot prospective study.

机构信息

Liver Surgery and Transplantation Unit, Digestive and Metabolism Diseases Clinical Institute, IDIBAPS, Hospital Clinic and Provincial, CIBERehd, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.

出版信息

Clin Transl Oncol. 2013 Sep;15(9):691-7. doi: 10.1007/s12094-012-0990-0. Epub 2013 Jan 30.

Abstract

PURPOSE

To analyze the use of proteomic profiles to discriminate healthy from patients with colorectal liver metastases (CLM) and to predict neoplastic recurrence after CLM resection.

METHODS

From April 2005 to October 2008, 70 patients operated for first curative resection of CLM and 60 healthy controls underwent determination of preoperative serum proteomic profile. We performed a preliminary training with patients and controls and obtained a classification system based on these patients' proteomic profiles training. The system was then tested about the ability to predict the colon versus rectum origin, metachronous or synchronous appearance, risk of recurrence after CLM resection and whether a sample was from a control or a CLM patient.

RESULTS

Sensitivity, specificity, positive and negative predictive values for detecting CLM patients were 75, 100, 100 and 54.6 %, respectively. Best CLM appearance time identification was 50 % and primary tumor origin identification was 62.5 %. Best classifications of neoplastic recurrence within the first year after CLM resection and during the follow-up period were 47.5 and 45 %, respectively. Larger training sets and prevalence-based training sets led to better classification of patients and characteristics.

CONCLUSION

Proteomic profiles are a promising tool for discriminating CLM patients from healthy patients and for predicting neoplastic recurrence.

摘要

目的

分析蛋白质组谱在鉴别结直肠肝转移(CLM)患者与健康人群以及预测 CLM 切除后肿瘤复发中的作用。

方法

2005 年 4 月至 2008 年 10 月,70 例首次接受 CLM 根治性切除术的患者和 60 例健康对照者进行了术前血清蛋白质组谱测定。我们对患者和对照者进行了初步的训练,并根据这些患者的蛋白质组谱训练获得了一个分类系统。然后,我们测试了该系统在预测结直肠原发灶、同步或异时性出现、CLM 切除后复发风险以及样本是否来自对照者或 CLM 患者方面的能力。

结果

检测 CLM 患者的敏感性、特异性、阳性预测值和阴性预测值分别为 75%、100%、100%和 54.6%。最佳 CLM 出现时间识别率为 50%,原发肿瘤起源识别率为 62.5%。对 CLM 切除后 1 年内和随访期间肿瘤复发的最佳分类分别为 47.5%和 45%。更大的训练集和基于患病率的训练集可更好地分类患者和特征。

结论

蛋白质组谱是一种很有前途的工具,可用于鉴别 CLM 患者与健康人群,以及预测肿瘤复发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验